<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: Although ", fill: "#008b8b"},
{source: "2: Although ", target: "2: approximately", fill: "#008b8b"},
{source: "2: approximately", target: "2: respectively", fill: "#008b8b"},
{source: "2: respectively", target: "2: most recent fiscal years", fill: "#008b8b"},
{source: "2: most recent fiscal years", target: "2: fiscal years", fill: "#008b8b"},
{source: "2: fiscal years", target: "2: December ", fill: "#008b8b"},
{source: "2: December ", target: "2: incurred net losses", fill: "#008b8b"},
{source: "2: incurred net losses", target: "2: Decembe ", fill: "#008b8b"},
{source: "2: Although ", target: "5: spending on research", fill: "#08e8de"},
{source: "5: spending on research", target: "5: development", fill: "#08e8de"},
{source: "5: development", target: "5: connection wit", fill: "#08e8de"},
{source: "5: connection wit", target: "5: sufficient revenues", fill: "#08e8de"},
{source: "5: sufficient revenues", target: "5: meet expenses", fill: "#08e8de"},
{source: "5: spending on research", target: "16: potential new products", fill: "#701c1c"},
{source: "16: potential new products", target: "16: commercially", fill: "#701c1c"},
{source: "16: commercially", target: "16: viable products from", fill: "#701c1c"},
{source: "16: viable products from", target: "16: applications", fill: "#701c1c"},
{source: "16: potential new products", target: "17: development", fill: "#967117"},
{source: "17: development", target: "17: manufacturing", fill: "#967117"},
{source: "17: manufacturing", target: "17: regulatory", fill: "#967117"},
{source: "17: development", target: "23: ColdEezeR ", fill: "#7c4848"},
{source: "23: ColdEezeR ", target: "23: development", fill: "#7c4848"},
{source: "23: ColdEezeR ", target: "32: whether new domestic", fill: "#a3c1ad"},
{source: "32: whether new domestic", target: "32: legislation regulating", fill: "#a3c1ad"},
{source: "32: legislation regulating", target: "32: activities will", fill: "#a3c1ad"},
{source: "32: whether new domestic", target: "33: new legislation coul", fill: "#c154c1"},
{source: "33: new legislation coul", target: "33: operations", fill: "#c154c1"},
{source: "33: new legislation coul", target: "START_HERE", fill: "#c154c1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tire_manufacturing">Tire manufacturing</a></td>
      <td>Pneumatic tires are manufactured according to relatively standardized processes and machinery, in around 455 tire factories in the world. With over 1 billion tires manufactured worldwide annually, the tire industry is a major consumer of natural rubber.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Zinc_gluconate">Zinc gluconate</a></td>
      <td>Zinc gluconate is the zinc salt of gluconic acid.  It is an ionic compound consisting of two anions of gluconate for each zinc(II) cation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Oldsmobile_88">Oldsmobile 88</a></td>
      <td>The Oldsmobile 88 (marketed from 1989 on as the Eighty Eight) is a full-size car that was sold and produced by Oldsmobile from 1949 until 1999. From 1950 until 1974, the 88 was the division's most profitable line, particularly the entry level models such as the 88 and Dynamic 88.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><font color="blue">Although  </font>we  earned  net  income  of  <font color="blue">approximately</font>  dlra3cmam217cmam000,  dlra453cmam000  an  d  dlra675cmam000, <font color="blue">respectively</font>, in our <font color="blue">most recent <font color="blue"><font color="blue">fiscal year</font>s</font></font> ended <font color="blue">December </font>31, 2005  ,  <font color="blue">December </font>31, 2004 and 2003, we <font color="blue">incurred net losses</font> of dlra6cmam454cmam000, dlra5cmam196cmam000 an  d  dlra4cmam204cmam000,  <font color="blue">respectively</font>, in the <font color="blue"><font color="blue">fiscal year</font>s</font> ended <font color="blue">December </font>31, 2002, <font color="blue">Decembe  </font>r  31, 2000 and <font color="blue">December </font>31, 1999</td>
    </tr>
    <tr>
      <td>In the <font color="blue">fiscal year</font> ended  <font color="blue">December </font>31, 2001, w  e  <font color="blue">earned net income</font> of dlra216cmam000,  but that amount included net settled  litigatio  n  <font color="blue">payments paid</font> to us of  <font color="blue">approximately</font>  dlra700cmam000 related to <font color="blue">licensing fees</font></td>
    </tr>
    <tr>
      <td>As o  f  <font color="blue">December </font>31, 2005, we had working capital of <font color="blue">approximately</font> dlra20cmam682cmam000</td>
    </tr>
    <tr>
      <td>Since w  e  continue to increase our <font color="blue">spending on research</font> and <font color="blue">development</font> in <font color="blue"><font color="blue">connection</font> wit</font>  h  Pharmaapstas  product  <font color="blue">development</font>,  we  are  uncertain  whether  we  will  generat  e  <font color="blue">sufficient revenues</font> to <font color="blue">meet expenses</font> or to operate profitably in the future</td>
    </tr>
    <tr>
      <td>WE HOLD PATENTS WHICH WE MAY NOT BE ABLE TO DEVELOP INTO PHARMACEUTICAL MEDICAT  IONS    Our  success  depends  in part on  Pharmaapstas  ability  to  research  and  develo  p  <font color="blue"><font color="blue">prescription</font> <font color="blue">medications</font> based on</font> our <font color="blue">patents which</font> are:         o    A Patent (Nodtta  6cmam555cmam573 B2) entitled   &amp;quote <font color="blue">Method and Composition </font>for th  e            Topical Treatment of Diabetic  Neuropathy &amp;quote</td>
    </tr>
    <tr>
      <td>o    A Patent (Nodtta 6cmam592cmam896 B2) entitled  &amp;quote <font color="blue">Medicinal Composition and Metho  </font>d            of Using It &amp;quote  (for <font color="blue">Treatment of <font color="blue">Sialorrhea  </font></font>and other  Disorders) for   a            product to relieve  <font color="blue">Sialorrhea  </font>(drooling) in patients  <font color="blue">suffering fro</font>  m            Amyotrophic  Lateral Sclerosis (ALS),  <font color="blue">otherwise known as</font> Lou Gehrig &amp;apos   s            Disease</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">patent extends</font> through</font> August 6, 2021</td>
    </tr>
    <tr>
      <td>o    A Patent (Nodtta  6cmam596cmam313  B2)  entitled   &amp;quote Nutritional  Supplement  an  d            <font color="blue">Method of Using It </font>&amp;quote  for a product to relieve <font color="blue">Sialorrhea  </font>(drooling) i  n            patients <font color="blue">suffering fro</font>m Amyotrophic Lateral Sclerosis (ALS), otherwis  e            known as Lou Gehrigapstas  Disease</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent extends</font>  through April 15  ,            2022</td>
    </tr>
    <tr>
      <td>o    A Patent  (Nodtta  6cmam753cmam325  B2)  entitled   &amp;quote Composition  and Method fo  r            Prevention,  Reduction  and  <font color="blue">Treatment  </font>of  Radiation  Dermatitis, &amp;quote     a            <font color="blue">composition</font>  for  the  preventing,   reducing  or  treating  radiatio  n            <font color="blue">dermatitis</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">patent extends</font> through</font> November 5, 2021</td>
    </tr>
    <tr>
      <td>o    A Patent (Nodtta 6cmam827cmam945 B2) entitled  &amp;quote Nutritional Supplement &amp; Method  s            of Using  Same &amp;quote  for a naturally  derived  compound  developed  for th  e            treatment of arthritis and related <font color="blue">inflammatory disorders</font></td>
    </tr>
    <tr>
      <td>The paten  t            <font color="blue">extends through</font> August 22, 2023</td>
    </tr>
    <tr>
      <td>-9-      These <font color="blue">potential <font color="blue">new products</font></font> are in the <font color="blue">development</font> stage and we cannot give an  y  assurances  that we can develop  <font color="blue">commercially</font>  <font color="blue">viable products from</font> these paten  t  <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>Prior to any new product  being  ready for sale,  we will have t  o  commit substantial  resources for research,  <font color="blue">development</font>,  preclinical  testing  ,  clinical  trials,  <font color="blue"><font color="blue">manufactur</font>ing</font>  scale-up  and  <font color="blue">regulatory</font>  approval</td>
    </tr>
    <tr>
      <td>We  fac  e  <font color="blue">significant</font>  <font color="blue">technological</font>  <font color="blue">risks inherent</font> in developing these products</td>
    </tr>
    <tr>
      <td>We ma  y  abandon some or all of our <font color="blue">proposed <font color="blue">new products</font></font> before they become commerciall  y  viable</td>
    </tr>
    <tr>
      <td>Even if we develop and obtain  approval of a new product,  if we canno  t  <font color="blue">successfully</font>  <font color="blue">commercialize</font>  it in a timely  manner,  our business and financia  l  <font color="blue">condition may</font> be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>WE  WILL  NEED  TO  OBTAIN  ADDITIONAL  CAPITAL  TO  SUPPORT  LONG-TERM  PRODUC  T  DEVELOPMENT AND COMMERCIALIZATION PROGRAMS    Our <font color="blue">ability t</font>o achieve and sustain operating <font color="blue"><font color="blue">profitability</font> depends</font> in large par  t  on our <font color="blue">ability t</font>o commence,  execute and  complete  clinical  programs  for, an  d  obtain <font color="blue">additional</font> <font color="blue">regulatory</font> approvals for,  <font color="blue">prescription</font>  <font color="blue">medications</font> develope  d  by Pharma,  <font color="blue">particularly</font>  in the US and Europe</td>
    </tr>
    <tr>
      <td>We cannot  assure you that w  e  will ever obtain such  approvals  or achieve  <font color="blue">significant</font>  levels of sales</td>
    </tr>
    <tr>
      <td>Ou  r  current sales levels of Cold-Eeze(R)  products and health and wellness  product  s  may not  generate  all the funds we  anticipate  will be needed to  support  ou  r  current  plans  for  product  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We may  need  to  obtain  additiona  l  financing to support our long-term  product  <font color="blue">development</font>  and  <font color="blue">commercializatio</font>  n  programs</td>
    </tr>
    <tr>
      <td>We may  seek  <font color="blue">additional</font>  funds  through  public  and  private  stoc  k  offerings,  <font color="blue">arrangements</font>  with  corporate  partners,  <font color="blue">borrowings</font>  <font color="blue">under lines o</font>  f  credit or other sources</td>
    </tr>
    <tr>
      <td>The amount of capital we may need to complete  product  <font color="blue">development</font>  of Pharma &amp;apos   s  products will <font color="blue">depend on</font> many factors, including;         o    the <font color="blue">cost involved</font> in applying for and obtaining FDA and  <font color="blue">internationa</font>  l            <font color="blue">regulatory</font> approvals;         o    whether we elect to establish partnering <font color="blue">arrangements</font> for <font color="blue">development</font>  ,            sales, <font color="blue"><font color="blue">manufactur</font>ing</font> and marketing of such products;         o    the level of future sales of our  Cold-Eeze(R) and health and wellnes  s            products,  expense  levels for our  <font color="blue">internationa</font>l  sales and marketin  g            efforts;         o    whether we can  establish  and  maintain  strategic  <font color="blue">arrangements</font>  fo  r            <font color="blue">development</font>, sales, <font color="blue"><font color="blue">manufactur</font>ing</font> and marketing of our products; and         o    whether  any or  all  of our  outstanding  options  and  warrants  ar  e            exercised and the timing and amount of these exercises</td>
    </tr>
    <tr>
      <td>If we need to rais  e  <font color="blue">additional</font>  funds and such funds are not <font color="blue">available on reasonable</font>  terms,  we ma  y  have to reduce  our  capital  <font color="blue">expenditures</font>,  scale back our  <font color="blue">development</font>  of ne  w  products,   reduce  our  workforce  and   out-license  to  others   products  o  r  <font color="blue">technologies</font>  that we  otherwise  would  seek to  <font color="blue">commercialize</font>  ourselves</td>
    </tr>
    <tr>
      <td>An  y  <font color="blue">additional</font>  equity  financing  will be  dilutive to  <font color="blue">stockholders</font>,  and any deb  t  financing, if available, may include <font color="blue">restrictive covenants</font></td>
    </tr>
    <tr>
      <td>OUR CURRENT  PRODUCTS  AND  POTENTIAL  NEW  PRODUCTS  ARE  SUBJECT TO  EXTENSIV  E  GOVERNMENTAL REGULATION    Our business is <font color="blue">regulated by various agencies</font> of the states and <font color="blue">localities wher</font>  e  our products are sold</td>
    </tr>
    <tr>
      <td><font color="blue">Governmental  </font><font color="blue">regulations</font> in foreign  countries where w  e  plan to  commence  or expand  sales may  prevent or delay entry into a market o  r  prevent or delay the <font color="blue">introduction</font>,  or require the <font color="blue">re<font color="blue">formulation</font></font>,  of <font color="blue">certain o</font>  f  our products</td>
    </tr>
    <tr>
      <td>In addition,  we cannot  predict  <font color="blue">whether new domestic</font> or foreig  n  <font color="blue">legislation regulating</font> our <font color="blue"><font color="blue">activities</font> will</font> be enacted</td>
    </tr>
    <tr>
      <td>Any <font color="blue">new legislation coul</font>  d  have  a  material  adverse  effect  on our  business,  financial  condition  an  d  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Non-compliance  with any applicable  requirements may subject us o  r  the  <font color="blue"><font color="blue"><font color="blue">manufactur</font>e</font>rs</font>  of our products to  sanctions,  including  warning  letters  ,  fines, product recalls and seizures</td>
    </tr>
    <tr>
      <td>COLD REMEDY AND HEALTH AND WELLNESS  PRODUCTS  The  <font color="blue"><font color="blue">manufactur</font>ing</font>,  processing  ,  <font color="blue">formulation</font>,  packaging,  labeling and <font color="blue">advertising</font> of our <font color="blue">cold remedy</font> and healt  h  and wellness  products are subject to  <font color="blue">regulation by several</font>  federal  agencies  ,  including:         o    the FDA;         o    the Federal Trade Commission ( &amp;quote FTC &amp;quote );                                            -10-           o    the Consumer Product Safety Commission;         o    the <font color="blue">United States </font>Department of Agriculture;         o    the <font color="blue">United States </font>Postal Service;         o    the <font color="blue">United States </font>Environmental Protection Agency; and         o    <font color="blue">the Occupational Safety and Health Administration</font></td>
    </tr>
    <tr>
      <td>In  particular,  the FDA  regulates  the safety,  labeling and  <font color="blue">distribution</font>  o  f  dietary  <font color="blue">supplements</font>,  including  vitamins,  minerals and herbs, food additives  ,  food <font color="blue">supplements</font>, over-the-counter and <font color="blue">prescription</font> drugs and cosmetics</td>
    </tr>
    <tr>
      <td>The FT  C  also has  overlapping  <font color="blue">jurisdiction</font>  with the FDA to regulate the  promotion an  d  <font color="blue">advertising</font>  of  vitamins,  over-the-counter  drugs,  cosmetics  and  foods</td>
    </tr>
    <tr>
      <td>I  n  addition,  our <font color="blue">cold remedy</font> products are <font color="blue"><font color="blue">homeopathic remedies whic</font>h</font> are regulate  d  by the Homeopathic  Pharmacopoeia of the <font color="blue">United States </font> ( &amp;quote HPUS &amp;quote )</td>
    </tr>
    <tr>
      <td>HPUS sets th  e  standards for source,  <font color="blue">composition</font> and <font color="blue">preparation</font> of <font color="blue">homeopathic remedies whic</font>  h  are <font color="blue">officially</font> recognized in the Federal Food, Drug and Cosmetics Act of 1938</td>
    </tr>
    <tr>
      <td><font color="blue">PHARMA The </font>preclinical <font color="blue">development</font>,  <font color="blue">clinical trials</font>, product <font color="blue"><font color="blue">manufactur</font>ing</font> an  d  marketing  of Pharmaapstas  potential  <font color="blue">new products</font> are subject to federal and stat  e  regulation in the <font color="blue">United States </font>and other countries</td>
    </tr>
    <tr>
      <td>Clinical trials and produc  t  marketing  and  <font color="blue"><font color="blue">manufactur</font>ing</font>  are subject to the  rigorous  review and approva  l  processes of the FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining FDA </font>and othe  r  required  <font color="blue">regulatory</font>  approvals is lengthy and expensive</td>
    </tr>
    <tr>
      <td>Typically,  obtainin  g  <font color="blue">regulatory</font> approval for <font color="blue">pharmaceutical</font>  products requires substantial  resource  s  and takes  several  years</td>
    </tr>
    <tr>
      <td>The  length  of this  process  depends  on the type  ,  <font color="blue">complexity</font>  and  novelty of the  product  and the nature of the disease or othe  r  <font color="blue">indication</font> to be treated</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font><font color="blue">studies must comply with</font> FDA <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Clinical  </font>trials  <font color="blue">must also comply with</font> FDA  <font color="blue">regulations</font>  and may require  larg  e  numbers of test  subjects,  complex  protocols  and possibly  lengthy  follow-u  p  periods</td>
    </tr>
    <tr>
      <td>Consequently,  <font color="blue">satisfaction</font> of government <font color="blue">regulations</font> may take severa  l  years,  may cause delays in introducing  <font color="blue">potential <font color="blue">new products</font></font> for considerabl  e  periods of time and may require <font color="blue">imposing costly</font>  <font color="blue">procedures upon</font> our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If we cannot obtain <font color="blue">regulatory</font> approval of <font color="blue">new products</font> in a <font color="blue">timely manner</font> or a  t  all we could be  <font color="blue">materially</font>  <font color="blue">adversely</font>  affected</td>
    </tr>
    <tr>
      <td>Even if we obtain  regulator  y  approval of <font color="blue">new products</font>,  <font color="blue">such approval may impose limitations on</font> the indicate  d  uses for  which  the  products  may be  marketed  which  could  also  materiall  y  <font color="blue">adversely</font> affect our business, <font color="blue">financial condition</font> and future <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>OUR  BUSINESS  IS  VERY  COMPETITIVE  AND  INCREASED  COMPETITION  COULD  HAVE   A  SIGNIFICANT IMPACT ON OUR EARNINGS    Both the non-<font color="blue">prescription</font>  healthcare product and <font color="blue">pharmaceutical</font>  <font color="blue">industries</font> ar  e  highly <font color="blue"><font color="blue">competitiv</font>e</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">substantially</font>  greater capita  l  resources,  research and <font color="blue">development</font>  staffs,  <font color="blue">facilities</font> and experience than w  e  do</td>
    </tr>
    <tr>
      <td>These and other  <font color="blue">entities may</font> have or may develop new  <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Thes  e  <font color="blue">technologies</font> may be used to develop products that <font color="blue">compete with ours</font></td>
    </tr>
    <tr>
      <td>We believe that our primary <font color="blue">cold remedy</font> product, Cold-Eeze(R), has a <font color="blue">competitiv</font>  e  <font color="blue">advantage over</font> other <font color="blue">cold remedy</font> products because it has <font color="blue">been clinically</font>  prove  n  to reduce the severity and duration of <font color="blue">common cold</font>  symptoms</td>
    </tr>
    <tr>
      <td>We believe Dariu  s  has an <font color="blue">advantage over</font> its <font color="blue">competitors</font>  because it <font color="blue">directly sells</font> its proprietar  y  health and  wellness  products  through  its  extensive  network of  independen  t  <font color="blue"><font color="blue"><font color="blue">distributo</font>r</font>s</font></td>
    </tr>
    <tr>
      <td>Competition in Pharmaapstas  expected product areas would most likel  y  come  from  large   <font color="blue">pharmaceutical</font>   companies  as  well  as  other   companies  ,  <font color="blue">universities</font>  and research  <font color="blue">institutions</font>,  many of which have  resources  far i  n  excess of our resources</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that its <font color="blue">ability t</font>o <font color="blue">compete depends on</font> a number of factors  ,  including price, product quality, availability, reliability and <font color="blue">name recognitio</font>  n  of its cold  remedy,  health  and  wellness  products  and  Pharmaapstas  <font color="blue">ability t</font>  o  <font color="blue">successfully</font>  develop  and  market  <font color="blue">prescription</font>  <font color="blue">medications</font></td>
    </tr>
    <tr>
      <td>There  can be n  o  assurance that we will be able to compete  <font color="blue">successfully</font> in the future</td>
    </tr>
    <tr>
      <td>If we ar  e  unable to compete, our <font color="blue">earnings may</font> be <font color="blue">significant</font>ly impacted</td>
    </tr>
    <tr>
      <td>In  particular,  the loss of the  services  of Guy J  Quigley,  ou  r  <font color="blue">Chairman  </font>of the  Board,  President  and Chief  Executive  Officer  could have   a  material adverse effect on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have an <font color="blue">employment agreement wit</font>  h  Mr</td>
    </tr>
    <tr>
      <td>Quigley <font color="blue">which expired on</font> <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our future  success and growt  h  <font color="blue">also depends on</font> our <font color="blue">ability t</font>o continue to attract,  motivate and retain  highl  y  <font color="blue">qualified employees</font></td>
    </tr>
    <tr>
      <td>If we are unable to attract,  motivate and retain qualifie  d  employees, our business and <font color="blue">operations</font> could be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>-11-      OUR FUTURE SUCCESS DEPENDS ON THE CONTINUED EMPLOYMENT OF RICHARD A ROSENBLOOM  ,  MD, PHD, WITH PHARMA    Pharmaapstas  <font color="blue">potential <font color="blue">new products</font></font> are being developed  through the efforts of Dr</td>
    </tr>
    <tr>
      <td>The loss of his <font color="blue">services could</font> have a material adverse effect on ou  r  product <font color="blue">development</font> and future <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>OUR FUTURE  SUCCESS  IS  DEPENDENT  ON THE  CONTINUED  ACCEPTANCE  OF THE DIREC  T  SELLING  PHILOSOPHY,  THE  MAINTENANCE  OF OUR NETWORK OF  EXISTING  INDEPENDEN  T  DISTRIBUTOR   REPRESENTATIVES  AND  THE  RECRUITMENT  OF  ADDITIONAL  SUCCESSFU  L  INDEPENDENT DISTRIBUTOR REPRESENTATIVES    Darius markets and <font color="blue">sells herbal</font>  vitamins and dietary  <font color="blue">supplements</font> for the huma  n  <font color="blue">condition through</font> its network of <font color="blue">independent</font>  <font color="blue"><font color="blue">distributo</font>r</font>  <font color="blue"><font color="blue">representative</font>s</font></td>
    </tr>
    <tr>
      <td>It  s  products are sold to <font color="blue">independent</font> <font color="blue"><font color="blue">distributo</font>r</font>  <font color="blue"><font color="blue">representative</font>s</font> who <font color="blue">either use th</font>  e  products for their own personal  <font color="blue">consumption</font>  or <font color="blue">resell them</font> to  consumers</td>
    </tr>
    <tr>
      <td>Th  e  <font color="blue">independent</font> <font color="blue"><font color="blue">distributo</font>r</font>  <font color="blue"><font color="blue">representative</font>s</font> receive <font color="blue">compensation</font> for sales achieve  d  by means of a <font color="blue">commission structure</font> or <font color="blue">compensation</font> plan <font color="blue">on certain product sale</font>  s  of  certain   personnel   within  their   downstream   <font color="blue">independent</font>   <font color="blue">distributo</font>  r  <font color="blue">representative</font>  network</td>
    </tr>
    <tr>
      <td>Since the <font color="blue">independent</font>  <font color="blue"><font color="blue">distributo</font>r</font>  <font color="blue"><font color="blue">representative</font>s</font> ar  e  not employees of Darius,  they are under no  <font color="blue">obligation</font>  to continue  buying an  d  selling  Darius &amp;apos   products  and the loss of key  high-level  <font color="blue"><font color="blue"><font color="blue">distributo</font>r</font>s</font>  coul  d  <font color="blue">negatively impact</font> our <font color="blue">future growth</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>OUR FUTURE SUCCESS DEPENDS ON THE CONTINUED SALES OF OUR PRINCIPAL PRODUCT    For  the  fiscal  year  ended  <font color="blue">December </font> 31,  2005,  our  Cold-Eeze(R)  product  s  represented <font color="blue">approximately</font> 55prca of our <font color="blue">total sales</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">diversified int</font>  o  health and <font color="blue">wellness products</font>,  our line of Cold-Eeze(R) <font color="blue">products continues</font> to b  e  a major part of our  business</td>
    </tr>
    <tr>
      <td>Accordingly,  we have to <font color="blue">depend on</font> the continue  d  <font color="blue">acceptance</font> of Cold-Eeze(R) <font color="blue">products by</font> our customers</td>
    </tr>
    <tr>
      <td>However,  there can be n  o  assurance  that our  Cold-Eeze(R)  products  will  continue  to  receive  marke  t  <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>The in<font color="blue">ability t</font>o  <font color="blue">successfully</font>  <font color="blue">commercialize</font>  Cold-Eeze(R)  in th  e  future,  for any reason,  would have a material  adverse effect on our financia  l  condition, prospects and <font color="blue">ability t</font>o continue <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>WE HAVE A CONCENTRATION  OF SALES TO AND ACCOUNTS  RECEIVABLE FROM SEVERAL LARG  E  CUSTOMERS    <font color="blue">Although  </font>we  have  a  broad  range  of  customers   that  includes  many  larg  e  <font color="blue">wholesalers</font>,  mass  <font color="blue">merchandisers</font> and <font color="blue">multiple outlet pharmacy chains</font>,  our fiv  e  <font color="blue">largest customers account</font> for a <font color="blue">significant</font>  percentage of our sales</td>
    </tr>
    <tr>
      <td>These fiv  e  customers  accounted  for 29prca of <font color="blue">total sales</font> for the <font color="blue">fiscal year</font> ended  <font color="blue">Decembe  </font>r  31, 2005 and 29prca of <font color="blue">total sales</font> for the <font color="blue">fiscal year</font> ended  <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>I  n  addition,  customers  comprising the <font color="blue">five largest <font color="blue">accounts</font></font>  receivable  balance  s  represented  47prca and 48prca of <font color="blue">total <font color="blue">accounts</font></font>  receivable  <font color="blue">balances at</font> <font color="blue">December </font>31  ,  2005 and 2004,  <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We extend credit to our  customers  <font color="blue">based upon</font> a  n  <font color="blue">evaluation</font>  of their  financial  condition  and  credit  history,  and we do no  t  <font color="blue">generally</font> require collateral</td>
    </tr>
    <tr>
      <td>If one or more of these large <font color="blue">customers cannot pa</font>  y  us, the write-off of their  <font color="blue">accounts</font>  receivable  would have a material  advers  e  effect on our <font color="blue">operations</font> and financial  condition</td>
    </tr>
    <tr>
      <td>The loss of sales to any on  e  or more of these large  customers  would also have a material  adverse effect o  n  our <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>WE ARE DEPENDENT ON THIRD-PARTY  MANUFACTURERS  AND SUPPLIERS FOR OUR HEALTH AN  D  WELLNESS  PRODUCTS  AND  THIRD-PARTY  SUPPLIERS  FOR  CERTAIN OF OUR COLD REMED  Y  PRODUCTS    We do not  <font color="blue"><font color="blue">manufactur</font>e</font>  any of  our  Health  and  <font color="blue">Wellness  </font>products,  nor do w  e  <font color="blue"><font color="blue">manufactur</font>e</font> any of the <font color="blue">ingredients</font> in these products</td>
    </tr>
    <tr>
      <td>In addition,  we purchas  e  all  active  <font color="blue">ingredients</font>  that are raw  materials  used in  <font color="blue">connection</font>  with ou  r  Cold-Eeze(R)  <font color="blue">product from</font> a <font color="blue">single unaffiliated</font>  supplier</td>
    </tr>
    <tr>
      <td>Should any of thes  e  <font color="blue"><font color="blue">relationship</font>s</font>  terminate,  we believe that the  <font color="blue">contingency</font>  plans which we hav  e  <font color="blue">formulated would prevent</font> a termination from <font color="blue">materially</font> affecting our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>However,  if any of these  <font color="blue">relationship</font>  is  terminated,  there may be delays i  n  production of our <font color="blue">products until</font> an acceptable  <font color="blue">replacement facility</font> is located</td>
    </tr>
    <tr>
      <td>We continue to look for safe and reliable multiple-location sources for product  s  and raw  materials so that we can continue to obtain  products and raw material  s  in the  event of a  <font color="blue">disruption</font>  in our  business  <font color="blue">relationship</font>  with any  singl  e  <font color="blue"><font color="blue">manufactur</font>e</font>r or supplier</td>
    </tr>
    <tr>
      <td>While we have identified <font color="blue">secondary sources</font> for some o  f  our products and <font color="blue">raw materials</font>,  our in<font color="blue">ability t</font>o find other sources for some o  f  our other  products and <font color="blue">raw materials</font> may have a material  adverse effect on ou  r  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition,  the <font color="blue">terms on which</font>  <font color="blue"><font color="blue"><font color="blue">manufactur</font>e</font>rs</font>  and <font color="blue">suppliers wil</font>  l  make products and <font color="blue">raw materials</font>  available to us could have a material effect o  n  our success</td>
    </tr>
    <tr>
      <td>WE ARE UNCERTAIN AS TO WHETHER WE CAN PROTECT OUR PROPRIETARY RIGHTS    The strength of our patent  <font color="blue">position may</font> be important to our long-term  success</td>
    </tr>
    <tr>
      <td>We  currently  own five  patents  in  <font color="blue">connection</font>  with  products  that are bein  g  developed by Pharma</td>
    </tr>
    <tr>
      <td>In addition,  we have <font color="blue">been granted</font> an exclusive  agreemen  t  for <font color="blue">worldwide representation</font>,  <font color="blue"><font color="blue">manufactur</font>ing</font>,  marketing and <font color="blue">distribution</font> right  s  to a  zinc/gluconate/glycine  lozenge  <font color="blue">formulation</font></td>
    </tr>
    <tr>
      <td>That  <font color="blue">formulation</font>  has bee  n  patented in the United States, Germany, France, Italy, Sweden, Canada and Great                                            -12-      <font color="blue">Britain  </font>and a patent is pending in Japan</td>
    </tr>
    <tr>
      <td>However,  this  patent in the Unite  d  States  expired in August 2004 and expired in June 2005 in all countries  excep  t  Japan</td>
    </tr>
    <tr>
      <td>There can be no  assurance  that these  patents and our  exclusive  <font color="blue">license wil</font>  l  <font color="blue">effectively protect</font> our <font color="blue">products from duplication by others</font></td>
    </tr>
    <tr>
      <td>In addition, we ma  y  not be able to afford the expense of any  <font color="blue">litigation</font>  which may be  <font color="blue">necessary t</font>  o  enforce  our rights  under any of our  patents</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  believe  that ou  r  current  and future  products do not and will not  infringe  upon the patents o  r  violate  the  <font color="blue">proprietary</font>  rights of  others,  if any of our  current  or futur  e  products do <font color="blue">infringe upon</font> the patents or  <font color="blue">proprietary</font>  rights of others,  we ma  y  have to modify our products or obtain an <font color="blue">additional</font>  license for the <font color="blue">manufactur</font>  e  and/or  sale of such  products</td>
    </tr>
    <tr>
      <td>We <font color="blue">could also</font> be  prohibited  from  <font color="blue">selling th</font>  e  infringing  products</td>
    </tr>
    <tr>
      <td>If we are found to infringe on the <font color="blue">proprietary</font>  rights o  f  others, we are <font color="blue">uncertain whether</font> we will be able to take <font color="blue">corrective actions</font> in   a  <font color="blue">timely manner</font>, upon acceptable terms and conditions,  or at all, and the failur  e  to do so could have a  material  adverse  effect  upon our  business,  financia  l  condition and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We also use non-disclosure agreements with our employees, suppliers, consultant  s  and customers to establish and protect the ideas,  concepts and <font color="blue"><font color="blue">documentation</font> o</font>  f  our confidential non-patented and non-copyright protected <font color="blue">proprietary</font> technolog  y  and know-how</td>
    </tr>
    <tr>
      <td>However, these <font color="blue">methods may</font> not afford complete protection</td>
    </tr>
    <tr>
      <td>Ther  e  can  be  no  assurance   that  third  parties  will  not  obtain  access  to  o  r  <font color="blue">independent</font>ly   develop  our  <font color="blue">technologies</font>,   know-how,   ideas,   concepts  an  d  <font color="blue">documentation</font>,  which  could have a  material  adverse  effect on our  financia  l  condition</td>
    </tr>
    <tr>
      <td>THE SALES OF OUR PRIMARY PRODUCT FLUCTUATES BY SEASON    A  <font color="blue">significant</font>  portion of our business is highly  seasonal,  which causes majo  r  <font color="blue">variations</font>  in operating  results <font color="blue">from quarter</font> to quarter</td>
    </tr>
    <tr>
      <td>The third and fourt  h  quarters  <font color="blue">generally</font>  represent  the  largest  sales  volume for our cold  remed  y  products</td>
    </tr>
    <tr>
      <td>There can be no assurance  that we will be able to manage our workin  g  capital needs and our inventory to meet the <font color="blue">fluctuating demand</font> for our products</td>
    </tr>
    <tr>
      <td>Failure to  <font color="blue">accurately</font>  predict and  respond to consumer  demand may cause us t  o  produce excess inventory</td>
    </tr>
    <tr>
      <td>Conversely,  if products achieve <font color="blue">greater success tha</font>  n  anticipated for any <font color="blue">given quarter</font>, we may not have sufficient  inventory to mee  t  <font color="blue">customer demand</font></td>
    </tr>
    <tr>
      <td>OUR  EXISTING  PRODUCTS  AND OUR NEW  PRODUCTS  UNDER  DEVELOPMENT  EXPOSE US T  O  POTENTIAL PRODUCT LIABILITY CLAIMS    Our  business  <font color="blue">exposes us</font> to an inherent  risk of  potential  product  liabilit  y  claims,  including claims for <font color="blue">serious bodily injury</font> or death caused by the sale  s  of our <font color="blue">existing products</font> and the <font color="blue">clinical trials</font> of our <font color="blue">products which</font> are bein  g  developed</td>
    </tr>
    <tr>
      <td>These claims could lead to substantial  <font color="blue">damage awards</font></td>
    </tr>
    <tr>
      <td>We currentl  y  maintain <font color="blue">product liability insurance</font> in the amount of, and with a maximum payou  t  of, dlra15 million</td>
    </tr>
    <tr>
      <td>A successful claim <font color="blue">brought <font color="blue">against us</font></font> in excess of, or outsid  e  of, our insurance  <font color="blue">coverage could</font> have a material  adverse effect on our result  s  of <font color="blue">operations</font> and financial  condition</td>
    </tr>
    <tr>
      <td>Claims <font color="blue">against us</font>,  regardless of thei  r  merit or  eventual  outcome,  may also  have a  material  adverse  effect on th  e  <font color="blue">consumer demand</font> for our products</td>
    </tr>
    <tr>
      <td>WE ARE  INVOLVED  IN  LAWSUITS  REGARDING  CLAIMS  RELATING  TO  CERTAIN  OF OU  R  COLD-EEZE(R) PRODUCTS    We are,  from time to time,  subject to various  legal  <font color="blue">proceedings</font>  and claims  ,  either  asserted or unasserted</td>
    </tr>
  </tbody>
</table>